Results 31 to 40 of about 4,485 (161)

Insulin detemir: From concept to clinical experience

Insulin detemir (Levemir\uae, Novo Nordisk) is a novel, biologically engineered analogue of human insulin that has been successfully developed for clinical use in diabetes as a basal insulin.
Kurtzhals P, Home P
core   +5 more sources

Metformin Inhibits Trophoblast Ferroptosis by Suppressing ATF2 and Activating the PI3K/Akt/Nrf2 Pathway to Improve Gestational Diabetes Mellitus

The FASEB Journal, Volume 40, Issue 18, 30 September 2026.
Metformin suppresses ATF2 expression, activating the PI3K/Akt pathway and promoting Nrf2 nuclear translocation. This upregulates GPX4, inhibiting ferroptosis in trophoblast cells. Erastin blocks system Xc−, depleting GSH and promoting ferroptosis. LY294002 and ML385 inhibit the pathway, validating the mechanism.
Dandan Xia, Yuhui Zhang, Wenjie Liu, Siyu Li, Chenying Zhang, Guangtong She, Huiyan Wang   +6 more
wiley   +1 more source

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7791-7801, September 2026.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock, Chantal Mathieu, Joshua Buron Feinberg, Priyanka Rao, Cathrine Scavenius, Alice Y. Y. Cheng   +5 more
wiley   +1 more source

Subgroups of Adult‐Onset Diabetes: A Prospective Follow‐Up Study of Progression of Insulin Resistance and Deficiency and Association With Liver Steatosis and Fibrosis

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8004-8015, September 2026.
ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen, Annemari Käräjämäki, Aki J. Käräjämäki, Samu Kurki, Liisa Hakaste, Olof Asplund, Johan Hultman, Kaj Lahti, Mikko Lehtovirta, Emma Ahlqvist, Tiinamaija Tuomi   +10 more
wiley   +1 more source

How the First 9 Months Shape the Rest of Your Life: The Impact of Gestational Diabetes on the Metabolic Future

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7705-7718, September 2026.
ABSTRACT Gestational diabetes mellitus (GDM) represents far more than a transient glycaemic disorder: it is a sentinel metabolic event that unveils pre‐existing defects in β‐cell function and insulin action, with profound implications for both maternal and offspring cardiometabolic health across the lifespan.
Mustafa Kanat, Muhammad Abdul‐Ghani, Ralph A. DeFronzo   +2 more
wiley   +1 more source

Impact of Early Subcutaneous Basal Insulin With Intravenous Insulin Infusion for Diabetic Ketoacidosis and Glycaemic Outcomes: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Early subcutaneous basal insulin initiation alongside intravenous insulin significantly shortened diabetic ketoacidosis resolution time and modestly reduced fluid requirements without increasing adverse events, supporting its potential role as a safe adjunctive strategy in adult DKA management.
Abdallah AbuJlambo, Maha AbuZarifa, Rejean R. R. Sawh, Subhash Reddy Narayana Reddy N, Muhammad Bin Salman, Insiya Mohammed Rampurawala, Yara Ashour, Hazem Ayesh   +7 more
wiley   +1 more source

Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance

Сахарный диабет, 2017
Combined glucose-lowering therapy, comprising of basal insulin with glucagon-like peptide-1 (GLP-1) analogues, has become central to the treatment of type 2 diabetes both at the start of insulin therapy, and as an alternative to basal-bolus insulin.
Lyudmila Alexandrovna Ruyatkina, Maxim Sorokin   +1 more
doaj   +1 more source

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review

Diabetes, Metabolic Syndrome and Obesity, 2009
Gregory E PetersonDepartment of Internal Medicine, Des Moines University, USAObjective: To review insulin detemir for clinical use to better manage patients with type 1 and type 2 diabetes.Methods: A MEDLINE search, in English, from June 30 ...
Gregory E Peterson
doaj  

Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6291-6300, July 2026.
ABSTRACT Aim To investigate adherence to and persistence with free combination therapy (daily basal insulin plus an injectable glucagon‐like peptide‐1 receptor agonist [GLP‐1 RA]) versus fixed‐ratio combination (FRC) therapy (basal insulin plus a GLP‐1 RA) among individuals with type 2 diabetes (T2D) in Japan.
Takeshi Miyatsuka, James Brash, Eleanor Davies, Elisabeth de Laguiche, Dorte Vistisen, Can Yin, Atif Adam   +6 more
wiley   +1 more source

Cost-Utility Analysis of the Use of Detemir in Patients with Type 2 Diabetes [PDF]

, 2015
Objetivo: realizar análise de custo-efetividade para avaliar o tratamento com as diferentes opções de insulina em pacientes diabéticos tipo 2. Metodologia: partindo da análise realizada previamente por Romero et al., foi atualizada a informação e incluiu-
Acero-Acero, Germán; Universitaria Monserrate, Romero-Prada, Martín Emilio; Universidad Nacional de Colombia, Páez, Mary Luz; Universidad del Rosario Pontificia Universidad Javeriana, Alfonso-Quiñones, Pamela Andrea; Universidad de La Sabana, Huérfano-Rey, Lina María; Pontificia Universidad Javeriana   +4 more
core   +2 more sources